ENGLEWOOD, Colo., Feb. 14, 2019 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announces that it will be ringing the Nasdaq Opening Bell at Times Square in New York on Thursday, February 21, 2019.
The ceremony commemorates Zynex's listing on the Nasdaq Capital Market on February 21, 2019. Thomas Sandgaard, Founder, Chairman and CEO is pleased to celebrate alongside Zynex's Board of Directors and members of the executive team honoring the Company's milestone achievement.
"The uplisting to Nasdaq is a milestone achievement for the Company, and one that we believe presents the opportunity for exposure to a broader and more diverse investor audience," said Mr. Sandgaard. "We would like to take this moment to thank and acknowledge the employees and investors who have supported the Company and helped facilitate the day."
The ceremony will be held at Nasdaq's MarketSite in New York City and will be webcast live on February 21, 2019, at 9:15 a.m. (Eastern Time) at https://new.livestream.com/nasdaq/live. In addition, photos and video of the Nasdaq Bell Ringing Ceremony will be available, courtesy of the Nasdaq, on Facebook (Nasdaq), Twitter (@Nasdaq), and YouTube.
About Zynex, Inc.
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: www.zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" or projections and as such are subject to numerous risks and uncertainties. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2017 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website.
Contact:
Zynex, Inc.
(303) 703-4906
Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
SOURCE Zynex, Inc.
